stockrow
Saturday 7 November 2026
Export ELAB’s income statement to Excel — free account
PMGC Holdings Inc.
ELAB Healthcare Biotechnology
PMGC Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $590,100.00, down 65.5% from fiscal 2023.
- Revenue
- +147.7%
- EPS
- +98.4%
- Free cash flow
- −45.0%
Quarter to June 2026, against a year earlier
1.63
0.02
−1.21%
Follow ELAB
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | 1 | 2 | — | 1 | 3 | (8.3%) | — | — | — | — | |
| Gross margin, % | — | — | — | — | — | — | 58.37 | 66.25 | — | 31.40 | 31.08 | (27.0) pt | ||||||
| EBT | — | — | — | — | — | — | (2) | (2) | (4) | (8) | (14) | +62.7% | ||||||
| EBT margin, % | — | — | — | — | — | — | (234.93) | (96.74) | 0.00 | (1,313.30) | (524.87) | (1,078.4) pt | ||||||
| Net income | — | — | — | — | — | — | (2) | (4) | (6) | (8) | (13) | +62.7% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.08 | 187,421.34 | 0.00 | 289.95 | 5.29 | +1,433.5% | |||||
| Earnings | — | — | — | — | — | — | (0.19) | (470,743.83) | (65,913.31) | (3,806.90) | (2,078.87) | +2,621.3% | ||||||
| Cash flow | — | — | — | — | — | — | (0.17) | (498,681.29) | (57,940.87) | (2,915.63) | (16.83) | +2,497.3% | ||||||
| Capex | — | — | — | — | — | — | 0.00 | (1,225.69) | (4,978.88) | (220.27) | (1.61) | +3,916.3% | ||||||
| Free cash flow | — | — | — | — | — | — | (0.17) | (499,906.98) | (62,919.75) | (3,135.91) | (18.44) | +2,543.3% | ||||||
| Book value | — | — | — | — | — | — | 0.12 | 418,825.31 | 70,323.13 | 3,850.92 | 34.33 | +3,089.4% | ||||||
| Shares, m | — | — | — | — | — | — | 10 | 0 | 0 | 0 | 0 | (94.0%) | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | — | 27,712,441.26 | 0.00 | — | 0.79 | 0.31 | 9,237,480.7 | ||||||
| P/B | — | — | — | — | — | — | 0.00 | 0.00 | — | 0.17 | 0.05 | 0.1 | ||||||
| EV/Sales | — | — | — | — | — | — | 27,712,440.93 | (1.94) | — | (2.63) | (6.87) | 9,237,478.8 | ||||||
| EV/FCF | — | — | — | — | — | — | (14,925,497.51) | 0.73 | — | 0.71 | 1.97 | (4,975,165.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (2) | (5) | (5) | (6) | (8) | +55.2% | |||||
| Capex | — | — | — | — | — | — | 0 | 0 | 0 | 0 | (1) | +141.1% | ||||||
| Free cash flow | — | — | — | — | — | — | (2) | (5) | (6) | (6) | (9) | +58.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 1 | 4 | 4 | 3 | 6 | +44.9% | |||||
| Net debt | — | — | — | — | — | — | (1) | (3) | (3) | (6) | (19) | +72.1% | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 1 | 4 | 7 | 8 | 17 | +90.6% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (121.48) | (88.07) | (70.88) | (58.71) | (70.9) pt | |||||
| ROIC | — | — | — | — | — | — | 0.00 | (142.57) | (71.34) | (220.80) | 0.00 | (220.8) pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | (173.52) | (119.12) | (106.89) | (104.60) | (106.9) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 16 | 18 | 3 | 34 | — | +28.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.05 | 0.10 | 0.00 | 0.02 | — | (28.7%) | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026
PMGC Holdings Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| ABPO Abpro Holdings Inc. | $1.4M | 0.5× | — | — | n/m | −0.48% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| KPTI Karyopharm Therapeutics Inc. | $1.4M | — (loss-making) | — (loss-making) | −11.86% (below 0%: shrinking) | n/m | −33.34% (below 0%: shrinking) | 96.75% | (67.38%) | Compare |
| ELAB PMGC Holdings Inc. | $1.3M | — (loss-making) | — | +147.70% (above 0%: growing) | n/m | −44.95% (below 0%: shrinking) | 29.52% | (292.91%) | |
| LABT Lakewood-Amedex Biotherapeutics Inc. | $1.3M | — (loss-making) | — | — | n/m | −420.66% (below 0%: shrinking) | — | 0.00% | Compare |
| PTIX Atrinsic Inc. | $1.3M | 0.2× | — | +34.31% (above 0%: growing) | n/m | +46.07% (above 0%: growing) | 0.00% | 0.00% | Compare |
| BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR | $1.3M | — (loss-making) | — | −32.27% (below 0%: shrinking) | +96.36% (above 0%: growing) | −0.17% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARTL Artelo Biosciences, Inc. | $1.2M | — (loss-making) | — | — | n/m | −879.18% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $1.3M | — | — | +11.23% | — | −13.09% | 48.38% | 0.00% |